What Accure Therapeutics does

Accure Therapeutics is a Barcelona-based private translational neuroscience R&D company founded in 2020 that develops first-in-class small-molecule drug candidates for central nervous system (CNS) disorders. The company operates a partnership-and-licensing business model: it advances candidates through early-to-mid clinical stages and then out-licenses them to pharmaceutical partners for late-stage development and commercialization, generating revenue through upfront payments, development and commercial milestone payments, and tiered royalties on net sales.

Its pipeline comprises three novel chemical entities, each targeting a distinct CNS pathology: ACT-01 (OCS-05), a neuroprotective small molecule that activates IGF-1 and BDNF trophic factor pathways to promote neuronal survival and repair and was licensed to Oculis in March 2022 (Oculis reported positive Phase 2 ACUITY results in January 2025); ACT-02, an orally active, brain-penetrant selective prolyl endopeptidase (PREP) inhibitor for Parkinson's disease, in IND-enabling studies with an IND filing planned for 2026; and ACT-03 (IPR-179), an injectable selective MMP-9/MMP-2 inhibitor for epilepsy at candidate-selection stage. ACT-01 carries orphan drug designation from both the US FDA and the EMA, and ACT-03 is protected by an international composition-of-matter patent granted across the US, Europe, Japan and other key markets.

Accure serves unmet medical need across four CNS indications - acute optic neuritis and glaucoma, multiple sclerosis, Parkinson's disease, and epilepsy - markets touching approximately 65 million epilepsy patients globally and a Parkinson's market estimated at $5.65 billion in 2024. The company has raised approximately $8.3 million in disclosed Series A equity led by Alta Life Sciences Spain I with CDTI support, supplemented by roughly $2.7 million of cumulative non-dilutive grants from the Catalan government (ACCIÓ), Spanish Ministry of Science, the Michael J. Fox Foundation and the Luxembourg National Research Fund. Headquarters are at the Barcelona Science Park; translational and clinical activities extend to France (APHP), Germany, the Netherlands, Luxembourg and the United States.

Name

Accure Therapeutics

Legal name

ACCURE Therapeutics S.L.

Website

https://accure.health

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Accure Therapeutics is a Barcelona-based private translational neuroscience R&D company developing first-in-class small-molecule drug candidates for optic neuritis, multiple sclerosis, Parkinson's disease, and epilepsy, advancing assets through early clinical stages and out-licensing to pharmaceutical partners.

Ownership category

akta.pro rank

Product category

CNS Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Central nervous system therapeutics
• Neurodegenerative disease drug development
• Clinical stage biotechnology
• Pharmaceutical licensing partnerships
• Disease-modifying CNS therapies

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Licensing and Milestone Payments: Accure develops drug candidates through early clinical stages and out-licenses to pharmaceutical partners. Revenue is generated through upfront payments, potential development and commercial milestone payments upon achievement of regulatory and sales milestones, and tiered royalties on net sales of licensed products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Accure Therapeutics is a private pharmaceutical R&D company developing three first-in-class new chemical entity programs for CNS disorders: ACT-01 (OCS-05) for neuroprotection in optic neuritis and multiple sclerosis (licensed to Oculis), ACT-02 for Parkinson's disease, and ACT-03 for epilepsy. The company operates a partnership and licensing business model, advancing early-stage drug candidates through translational development before out-licensing to partners for clinical development and commercialization. Revenue is generated through upfront payments, milestone payments, and tiered royalties on net sales of licensed products.

Product overview

Accure Therapeutics is a private translational neuroscience R&D company developing three first-in-class new chemical entity programs for CNS disorders: ACT-01 (OCS-05) for neuroprotection in optic neuritis and multiple sclerosis (licensed to Oculis), ACT-02 for Parkinson's disease, and ACT-03 for epilepsy. The company operates a partnership and licensing business model, advancing early-stage drug candidates through translational development before out-licensing to partners for clinical development and commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• ACT-01 (OCS-05) First-in-class neuroprotective small molecule originally developed for acute optic neuritis and glaucoma, with potential applications in multiple sclerosis and other neurodegenerative diseases. The compound activates trophic factor pathways (IGF-1 and BDNF) to promote cell survival and endogenous repair of damaged neurons, crosses the blood-brain barrier via active transport, and has received orphan drug designation from the US FDA and EMA for acute optic neuritis. Licensed to Oculis for global ophthalmology development and commercialization.
• ACT-02 First-in-class orally active, brain-penetrant selective inhibitor of Prolyl Endopeptidase (PREP) being developed as a disease-modifying therapy for Parkinson's disease. The compound has a dual mechanism of action targeting key pathological pathways, demonstrating reduction of alpha-synuclein aggregation, neuroinflammation reduction, and improved mitochondrial functioning in preclinical models. Currently in IND-enabling stage with IND filing planned for 2026.
• ACT-03 (IPR-179) Injectable, brain-penetrant small molecule and selective inhibitor of matrix metalloproteinases (MMP-9 and MMP-2), being developed for epilepsy including post-traumatic epilepsy. The compound modulates neuroplasticity and neuroinflammation at the extracellular matrix level and has demonstrated ability to reduce number, intensity, and duration of seizures in preclinical epilepsy models. Protected by an international composition-of-matter patent granted in the US, Europe, Japan, and other key markets.

Quantifiable outcome

• ACT-01 Phase 2 ACUITY trial met primary safety endpoint and key secondary efficacy endpoints with no serious adverse events
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and major.

• OculiscoreOEM/ Whitelabel/ Licensing Partner · 2 March 2022Licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01 (renamed OCS-05) for ophthalmology indications including acute optic neuritis and glaucoma. Oculis completed positive Phase 2 ACUITY trial and is expanding development in US, EU, and China. Accure receives upfront payment, milestone payments, and tiered royalties on sales.
• Centro Vasco de Neurociencia Achucarro (UPV/EHU)majorStrategic or Co-development PartnerConsortium partner with Accure and UPF receiving €1M Spanish Ministry grant for ACT-03 evaluation in post-traumatic epilepsy preclinical models.
• Universidad Pompeu Fabra (UPF)majorStrategic or Co-development PartnerConsortium partner with Accure and Achucarro for €1M Spanish Ministry project on ACT-03 in post-traumatic epilepsy.
• Stiftung Tierärztliche Hochschule Hannover (Institute of Pharmacology, Toxicology and Pharmacy)majorStrategic or Co-development PartnerAcademic partner for MJFF-funded ACT-02 project, led by Prof. Dr. Franziska Richter Assencio, conducting preclinical studies for Parkinson's disease IND application.
• Luxembourg Centre for Systems Biomedicine (LCSB)majorStrategic or Co-development PartnerFNR BRIDGES project partner led by Prof. Rejko Krüger assessing ACT-02 efficacy in human iPSC-derived neurons for precision medicine in Parkinson's disease.
• University of Amsterdam / Amsterdam UMCmajorStrategic or Co-development PartnerCollaborated with Dr. Erwin Van Vliet and Dr. Eleonora Aronica on ACT-03 preclinical epilepsy research, studying effects on astrogliosis, microgliosis, and blood-brain barrier integrity.
• German Center for Neurodegenerative Diseases (DZNE)majorStrategic or Co-development PartnerCollaborated with Dr. Alexander Dityatev's molecular neuroplasticity group on ACT-03 research funded by EU Horizon 2020 and FP7 programs.
• Public University Hospital Group in Paris (APHP)majorStrategic or Co-development PartnerClinical trial site for Phase 2 ACUITY study at La Pitié-Salpêtrière hospital under Dr. Céline Louapre and Dr. Sophie Bonnin, within the Paris Brain Institute (ICM).

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Minoryx Therapeutics: Spain-based clinical-stage CNS biotech developing disease-modifying therapies for rare neurodegenerative diseases (X-linked adrenoleukodystrophy). Comparable in size, stage, geography, and translational CNS R&D focus.
• Anavex Life Sciences: Clinical-stage biotech developing orally available disease-modifying treatments for CNS diseases including Alzheimer's, Parkinson's, and Rett syndrome via sigma-1 receptor activation. Closely comparable mechanism-of-action ethos and clinical-stage CNS focus.
• Bionure: CNS-focused biotech previously founded by Accure's CSO Dr. Pablo Villoslada, developing neuroprotective small molecules for multiple sclerosis and optic neuritis. Highly comparable therapeutic focus and scientific lineage.
• Prexton Therapeutics: Clinical-stage Swiss CNS biotech developing therapies for Parkinson's disease (foliglurax), where Accure's CMO Dr. Rossella Medori previously served as CMO prior to its ~€905M acquisition by Lundbeck/Sumitomo. Highly comparable CNS Parkinson's focus and stage.

Broad incumbents

• Sage Therapeutics: Clinical-stage CNS biotech with multiple approved and pipeline assets (Zulresso, Zurzuvae) for depression, epilepsy, and CNS disorders. Comparable CNS-focused, partnership-driven business model at greater scale.
• Prothena Corporation: Clinical-stage biotech developing protein immunotherapy approaches for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable disease-modifying CNS focus and partnership-based business model.
• Denali Therapeutics: Clinical-stage biotech developing disease-modifying therapies for neurodegeneration (Parkinson's, Alzheimer's, ALS) and other serious diseases. Comparable CNS pipeline depth and scientific rigor, at significantly larger scale.

Emerging players

• Stoke Therapeutics: Clinical-stage biotech using antisense oligonucleotide technology to address the underlying cause of severe CNS diseases (Dravet syndrome, ADOA). Comparable stage, CNS focus, and rare-disease orphan strategy.
• Alterity Therapeutics: Clinical-stage biotech developing disease-modifying therapies for neurodegenerative diseases including Parkinson's and multiple system atrophy. Comparable CNS disease-modifying focus at similar stage.

Others

• Oculis Holding: Clinical-stage ophthalmology biotech that licensed ACT-01 (OCS-05) from Accure in 2022 and successfully completed the Phase 2 ACUITY trial. Direct counterparty partner with adjacent CNS/ophthalmology positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accure Therapeutics